ESRP2 and prostate carcinoma: Consistent with Casodex preventing expression of some potentially harmful isoforms in prostate cancer cells, the splicing inclusion of NUMB exon three and TUFT1 exon two were reduced by Casodex (both these exons are normally activated by androgen exposure and ESRP2).